Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages

Vaccine

Volumn 27, Issue SUPPL.6, 2009, Pages

  Gray, Andrew ^a   de la Luz Garcia Hernandez, Maria ^a   van West, Myrna ^a   Kanodia, Shreya ^a   Hubby, Bolyn ^b   Kast, W Martin ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b AlphaVax Inc   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Immunotherapy; Prostate cancer; Regulatory T cells

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; EARLY CANCER; GENE GUN IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; TRANSGENIC ADENOCARCINOMA MOUSE PROSTATE; TRANSGENIC MOUSE;

ANIMALS; CANCER VACCINES; CELL PROLIFERATION; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; VACCINES, DNA;

EID: 72049130810     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.106     Document Type: Article

References (34)

1. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J Clin 52 January-February (1) (2002) 23-47
2. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 June (6) (1996) 1756-1764
3. Hillman G.G., Triest J.A., Cher M.L., Kocheril S.V., and Talati B.R. Prospects of immunotherapy for the treatment of prostate carcinoma-A review. Cancer Detect Prev 23 4 (1999) 333-342
4. Crawford E.D., Rosenblum M., Ziada A.M., and Lange P.H. Hormone refractory prostate cancer. Urology 54 December (6A Suppl.) (1999) 1-7
5. Noguchi M., Kobayashi K., Suetsugu N., Tomiyasu K., Suekane S., Yamada A., et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57 September (1) (2003) 80-92
6. Garcia-Hernandez Mde L., Gray A., Hubby B., and Kast W.M. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 67 February (3) (2007) 1344-1351
7. Ross S., Spencer S.D., Holcomb I., Tan C., Hongo J., Devaux B., et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 62 May (9) (2002) 2546-2553
8. Zhu Z.Y., Zhong C.P., Xu W.F., Lin G.M., Ye G.Q., Ji Y.Y., et al. PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response. Cell Res 9 December (4) (1999) 271-280
9. Wang Y., Harada M., Yano H., Ogasawara S., Takedatsu H., Arima Y., et al. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother 28 November-December (6) (2005) 535-541
10. Gray A., Raff A.B., Chiriva-Internati M., Chen S.Y., and Kast W.M. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 222 April (2008) 316-327
11. Curiel T.J. Regulatory T cells and treatment of cancer. Current opinion in immunology 20 April (2) (2008) 241-246
12. Gabrilovich D.I., and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev 9 March (3) (2009) 162-174
13. Katz J.B., Muller A.J., and Prendergast G.C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222 April (2008) 206-221
14. Bronte V., and Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev 5 8 (2005) 641-654 Aug
15. Wrzesinski S.H., Wan Y.Y., and Flavell R.A. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13 September (18 Pt 1) (2007) 5262-5270
16. Kretschmer K., Apostolou I., Jaeckel E., Khazaie K., and von Boehmer H. Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev 212 August (2006) 163-169
17. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92 8 (1995) 3439-3443 Apr 11
18. Reiter R.E., Gu Z., Watabe T., Thomas G., Szigeti K., Davis E., et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95 4 (1998) 1735-1740 Feb 17
19. Yang D., Holt G.E., Velders M.P., Kwon E.D., and Kast W.M. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61 August (15) (2001) 5857-5860
20. Garcia-Hernandez Mde L., Gray A., Hubby B., Klinger O.J., and Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68 February (3) (2008) 861-869
21. Garcia-Hernandez M.L., Hernandez-Pando R., Gariglio P., and Berumen J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 105 February (2) (2002) 231-243
22. Koh Y.T., Gray A., Higgins S.A., Hubby B., and Kast W.M. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 69 May (6) (2009) 571-584
23. Gingrich J.R., Barrios R.J., Kattan M.W., Nahm H.S., Finegold M.J., and Greenberg N.M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57 November (21) (1997) 4687-4691
24. Miller A.M., Lundberg K., Ozenci V., Banham A.H., Hellstrom M., Egevad L., et al. CD4+ CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177 November (10) (2006) 7398-7405
25. Yokokawa J., Cereda V., Remondo C., Gulley J.L., Arlen P.M., Schlom J., et al. Enhanced functionality of CD4+ CD25 (high) FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 14 February (4) (2008) 1032-1040
26. Degl'Innocenti E., Grioni M., Capuano G., Jachetti E., Freschi M., Bertilaccio M.T., et al. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res 68 January (1) (2008) 292-300
27. Mocellin S., Panelli M.C., Wang E., Nagorsen D., and Marincola F.M. The dual role of IL-10. Trends Immunol 24 January (1) (2003) 36-43
28. Nath A., Chattopadhya S., Chattopadhyay U., and Sharma N.K. Macrophage inflammatory protein (MIP)1alpha and MIP1beta differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy. Cancer Immunol Immunother 55 December (12) (2006) 1534-1541
29. Matsukawa A., Lukacs N.W., Standiford T.J., Chensue S.W., and Kunkel S.L. Adenoviral-mediated overexpression of monocyte chemoattractant protein-1 differentially alters the development of Th1 and Th2 type responses in vivo. J Immunol 164 February (4) (2000) 1699-1704
30. Curcio C., Di Carlo E., Clynes R., Smyth M.J., Boggio K., Quaglino E., et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 111 April (8) (2003) 1161-1170
31. Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203 April (4) (2006) 941-951
32. Chen W., Liang X., Peterson A.J., Munn D.H., and Blazar B.R. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 181 October (8) (2008) 5396-5404
33. Chung D.J., Rossi M., Romano E., Ghith J., Yuan J., Munn D.H., et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood May (2009) 22
34. Sharma M.D., Hou D.Y., Liu Y., Koni P.A., Metz R., Chandler P., et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113 June (24) (2009) 6102-6111